Company intelligence / Profile preview

ISAR Bioscience

Planegg, Bavaria, Germanyisarbioscience.de ↗

Ownership: Private
Employees: ~27
Development stage: Other

Overview

ISAR Bioscience develops regenerative therapies using iPS cells and differentiated human cells to address dementia, heart failure, immune diseases, and infectious diseases. Their pipeline includes early-stage programs targeting TREM2 for cognition disorders and nanobody-based approaches against viral proteins. No clinical results or advanced-stage assets are reported as of mid–2025.

Therapeutic areas: Infectious DiseasesImmunologyNeurologyCardiovascular
Modalities: Induced pluripotent stem cell derived therapy (iPSC-derived therapy)Monoclonal antibodyNanobody therapyCell therapyGenome engineering-based therapies
Industry: Biotech

Drug pipeline

3 assets

M07-TFN

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ISAR Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISAR Bioscience.

Explore the full profile